- Home
- SCNI
as 12-18-2024 1:42pm EST
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 3.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 13.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.23 - $8.92 | Next Earning Date: | 11-22-2024 |
| Revenue: | $452,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Scinai Immunotherapeutics Ltd. News
SCNI Breaking Stock News: Dive into SCNI Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
PR Newswire
13 days ago
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Simply Wall St.
19 days ago
There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability
PR Newswire
21 days ago
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
PR Newswire
a month ago
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
PR Newswire
2 months ago
Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
PR Newswire
3 months ago
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
PR Newswire
4 months ago
Scinai Regains Full Compliance with Nasdaq Listing Requirements
Compare SCNI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SCNI Scinai Immunotherapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.